Citizens raises Progyny stock price target on guidance increase
Citizens raised its price target for Progyny (PGNY) to $38.00 from $33.00, citing increased guidance. The firm adjusted its 2027 revenue estimate to $1.526B and raised its Q4 revenue estimate to $360M. Progyny's Q3 2026 earnings beat expectations, with revenue of $341.25M and EPS of $0.32. The company added 1.3M new covered lives and 85 new clients.
How this was made
The 30-second read
Why it matters
Analyst upgrade with higher price target and revised Q4 guidance could drive short‑term buying interest.
Market read
The new guidance and target raise provide fresh actionable information for traders focused on health‑benefits stocks.
What to watch
Potential headwinds from employer cost‑containment could curb future growth.
Background
Progyny offers fertility and family‑building benefits management services and recently reported Q3 2026 earnings that beat expectations.
Ticker impact
Citizens raised its price target on Progyny to $38 from $33 and lifted Q4 revenue and EBITDA estimates.
potential upward pressure as investors price in the higher target and improved forecasts
Analyst upgrade with concrete numbers typically moves the stock in the direction of the new target.
Market effects
Positive guidance may lift other fertility‑benefits providers in the health‑benefits sector.
Limited to U.S. listed health‑benefits stocks.
Minimal global impact beyond niche sector.
Counterpoint
The target raise may already be priced in, limiting upside.
Key entities
- analystCitizens
Equity research firm that raised PGNY price target.
- companyProgyny
Provider of fertility benefits management services.
